CRLconf 0.85

balstilimab — CRL

$AGEN · AGENUS INC · second-line cervical cancer

Event date

Date TBD

Sponsor runway

3 mo

$35.0M liquid

Evidence

“Company voluntarily withdraws BLA at FDA's recommendation following full approval of pembrolizumab, which came four months earlier than FDA goal date”

Source: Press release · 2021-10-22View press release ↗

Comparable historical crls· last 5 years · same event type

No comparable historical outcomes in our database yet — backfill of past readouts arrives next ingestion cycle.

Recent insider activity· ±90 days

1 insider · 0 buys · 0 sells

Grant

2026-05-15

ARMEN GARO H

See Remarks

4,540 @ $3.58$16K

Grant

2026-05-01

ARMEN GARO H

See Remarks

4,233 @ $3.84$16K

Date	Insider	Action	Shares	Price	Value
2026-05-15	ARMEN GARO HSee Remarks	Grant	4,540	$3.58	$16K
2026-05-01	ARMEN GARO HSee Remarks	Grant	4,233	$3.84	$16K

← All catalysts for $AGEN